EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieVergleichsstudieÄquivalenzstudieOpen Access · CC BY 4.0

Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non‐inferiority study

Kyoungwon Jung iD, Sam Ryong Jee iD, Moon Won Lee iD, Myeongseok Koh iD, Su Jin Kim iD, Jin Lee iD, Moo In Park iD

Helicobacter · 2024

DOI: 10.1111/hel.13084 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Helicobacter, 2024. Verfasst von Kyoungwon Jung und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea. Hauptthemen laut MEDLINE: Helicobacter Infections, Clarithromycin, Helicobacter pylori, Anti-Bacterial Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korean College of Helicobacter and Upper Gastrointestinal Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recently, a simple tailored therapy based on clarithromycin resistance has been implemented as Helicobacter pylori ( H. pylori ) eradication therapy. Nonetheless, despite the tailored therapy and frequent adverse events, studies on treatment period are lacking. This study aimed to compare the H. pylori eradication rates of 7‐day and 14‐day tailored therapy regimens according to clarithromycin resistance. Materials and Methods This multicenter, prospective, randomized, noninferiority trial enrolled H. pylori ‐positive patients who were randomly assigned to 7‐day and 14‐day regimen groups, depending on the presence or absence of clarithromycin resistance by 23S rRNA gene point mutations. Standard triple therapy (STT) (20 mg rabeprazole, 1 g amoxicillin, and 500 mg clarithromycin twice daily) or bismuth quadruple therapy (BQT) (20 mg rabeprazole twice daily, 500 mg metronidazole thrice daily, 120 mg bismuth four times daily, and 500 mg tetracycline four times daily) was assigned by clarithromycin resistance. Eradication rates and adverse events were evaluated.

Results

A total of 314 and 278 patients were included in the intention‐to‐treat (ITT) and per‐protocol (PP) analyses, respectively; however, 31 patients were lost to follow‐up, whereas five patients violated the protocol. Both the 7‐day and 14‐day regimens showed similar eradication rates in the ITT (7‐day vs. 14‐day: 78.3% vs. 78.3%, p > 0.99) and PP (87.9% vs. 89.1%, p = 0.851) analyses. Non‐inferiority was confirmed ( p < 0.025). A subgroup analysis according to clarithromycin resistance (clarithromycin resistance rate: 28.7%) revealed no significant difference in eradication rates between the 7‐day and 14‐day STT (90.0% vs. 90.1%, p > 0.99) and BQT (82.5% vs. 86.5%, p = 0.757). Furthermore, adverse events did not significantly differ between the two groups.

Conclusions

The 7‐day triple and quadruple therapy according to clarithromycin resistance showed similar eradication rates, as compared to the 14‐day therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsClarithromycinHelicobacter pyloriAnti-Bacterial AgentsDrug Resistance, BacterialHumansMaleFemaleMiddle AgedAdultProspective StudiesDrug Therapy, CombinationAgedTreatment OutcomeRabeprazoleBismuthRNA, Ribosomal, 23S

Stichwörter der Autor:innen

Helicobacter pyloriclarithromycin resistancetreatment duration

Substanzen

ClarithromycinAnti-Bacterial AgentsRabeprazoleBismuthRNA, Ribosomal, 23S

Autor:innen und Institutionen

  • Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea.
  • Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
  • Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea.
  • Department of Internal Medicine, Dong-A University Hospital, Dong-A University College of Medicine, Busan, Republic of Korea.
  • Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Gyeongsangnam-do, Republic of Korea.
  • Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.

ORCID-Profile: Kyoungwon Jung, Sam Ryong Jee, Moon Won Lee, Myeongseok Koh, Su Jin Kim, Jin Lee, Moo In Park

Förderung

  • Korean College of Helicobacter and Upper Gastrointestinal Research

Zitieren

APA

Jung, K., Jee, S. R., Lee, M. W., Koh, M., Kim, S. J., Lee, J., & Park, M. I. (2024). Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non‐inferiority study. Helicobacter. https://doi.org/10.1111/hel.13084

Vancouver

Jung K, Jee SR, Lee MW, Koh M, Kim SJ, Lee J, et al. Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non‐inferiority study. Helicobacter. 2024. doi:10.1111/hel.13084

BibTeX
@article{Jung2024,
  author = {Jung, Kyoungwon and Jee, Sam Ryong and Lee, Moon Won and Koh, Myeongseok and Kim, Su Jin and Lee, Jin and Park, Moo In},
  title = {Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non‐inferiority study},
  journal = {Helicobacter},
  year = {2024},
  doi = {10.1111/hel.13084}
}
Kostenlos starten →